866-997-4948(US-Canada Toll Free)

MediPoint: In-Vitro Colorectal Cancer Screening Tests - APAC Analysis and Market Forecasts

Published By :

GlobalData

Published Date : Aug 2013

Category :

Cancer

No. of Pages : 322 Pages


Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

GlobalData has estimated the APAC region in-vitro CRC screening market to grow at a compound annual growth rate (CAGR) of 1.25% over the next seven years. This slow growth can be attributed to an aging population in Japan (increasing the screening population); emerging new higher-priced gene tests which offer better specificity and sensitivity, and slow adoption of organised CRC screening programs in China and India.

Scope

  • An overview of colorectal cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. 
  • Annualized APAC in-vitro colorectal cancer screening tests market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019. 
  • Investigation of current and future market competition for in-vitro colorectal cancer screening tests
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. 
  • Competitor assessment including device approval analysis and device sales forecasts. 
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. 
  • Analysis of unmet needs within the market and opportunities for future players. 
  • Technology trends evaluation to assess strength of pipeline. 
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. 
  • Company profiles including business description, financial overview and SWOT analysis. 
  • Coverage of key market players. 
  • Strategic assessment of the in-vitro colorectal cancer screening tests sector through market impact analysis, future market scenario and company analysis. 
  • Direct quotes from Key Opinion Leaders (KOL)

Reasons to buy

  • Understand the trends shaping and driving the APAC in-vitro colorectal cancer screening tests Market. 
  • Realize device preferences of physicians who have performed the tests already. 
  • Access market sizing, forecasts and quantified growth opportunities in the APAC in-vitro colorectal cancer screening tests market through 2019. 
  • Quantify candidate patient populations to better design product pricing & launch plans. 
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. 
  • Perform benchmarking analysis of growth opportunities against currently marketed products. 
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. 
  • Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products. 
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. 
  • Whats the next big thing in the APAC in-vitro colorectal cancer screening tests market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 21

2 Introduction 23
2.1 Catalyst 23

3 Disease Overview 24
3.1 Colorectal Cancer 24
3.2 Anatomy and Physiology 24
3.3 Pathophysiology 25
3.3.1 Histology 25
3.3.2 Genetic Basis 26
3.3.3 Etiology of CRC 27
3.4 Clinical Presentation 29
3.4.1 Symptoms 29
3.4.2 Screening Overview 30
3.4.3 Status of National CRC Screening Programs 31
3.4.4 Diagnosis Overview 32
3.4.5 Staging Colorectal Cancer 37
3.5 Clinical Outcomes 40
3.5.1 Treatment Paradigms 40
3.5.2 Treatment Options Overview 41
3.6 Epidemiology 43
3.6.1 Regional and Historical Trends 43
3.6.2 Japan 43
3.6.3 China 44
3.6.4 India 44
3.7 Epidemiology Forecast (2010-2019) 45
3.7.1 Total Incident Cases of Colorectal Cancer 45
3.8 Economic Impact 46
3.8.1 Individual Costs 46

4 Competitive Assessment 49
4.1 Overview 49
4.2 Fecal Occult Blood Tests 49
4.2.1 Guaiac Fecal Occult Blood Stool Tests 49
4.2.2 Lateral Flow Immuno-Fecal Occult Blood Tests 53
4.2.3 Readers 61
4.2.4 Immuno-FOB Test ELISA 64
4.2.5 Immuno-FOB Agglutination Tests 67
4.3 CRC DNA Screening Tests 77
4.3.1 Panel DNA Tests 77
4.3.2 Methylated Gene Testing 87
4.4 Other Biomarker Tests 95
4.4.1 Overview 95
4.4.2 Tumor M2-PK Stool Test/2-in-1 Quick Test 96
4.4.3 Transferrin Assays 99

5 Unmet Needs 101
5.1 False Negative Results 101
5.2 False Positive Results 103
5.3 Sample Type 105
5.4 Screening Compliance 106
5.5 Alternative to Colonoscopy 109
5.6 Accurate Early Staging of Colorectal Cancer 111
5.7 Screening Test Alternatives 112
5.8 Automation 113

6 Pipeline Products 115
6.1 Overview 115
6.2 Pipeline by Phases in Development 115
6.3 Pipeline Product Profiles 117
6.3.1 BST1 CRC Assay 117
6.3.2 Cologic 118
6.3.3 ColoGuard 120
6.3.4 Colon Cancer BEC Test 124
6.3.5 Colon MarCare Plex 125
6.3.6 Colox 128
6.3.7 CRC Bacterial Signature Assay 130
6.3.8 CRC Breath Test 131
6.3.9 Epi proColon 134
6.3.10 ExiQon MicroRNA Test 140
6.3.11 Gemini CRC Biomarker Assay 143
6.3.12 GenomicTree Methylated DNA Test 144
6.3.13 Measure Fecal Occult Blood Test 146
6.3.14 Metabiomics CRC Test 149
6.3.15 MiR-21 Test 151
6.3.16 Oncolite CR 153
6.3.17 PanC-Dx 155

7 Industry Overview 158
7.1 Colorectal Cancer Screening Test Trends 158
7.1.1 Japan 158
7.1.2 China 159
7.1.3 India 160
7.2 Market Access 162
7.3 Reimbursement Trends 164
7.3.1 Japan 164
7.3.2 China 164
7.3.3 India 167
7.4 Regulatory Issues and Recalls 168
7.4.1 APAC Region Regulation 168
7.4.2 US 169
7.4.3 5EU 171
7.4.4 Recalls 171
7.5 Mergers and Acquisitions 172

8 Current and Future Players 173
8.1 Overview 173
8.2 Trends in Corporate Strategy 174
8.3 Company Profiles 175
8.3.1 Abbott Molecular 175
8.3.2 Alere 176
8.3.3 Beckman Coulter 179
8.3.4 Biomarcare Technologies 180
8.3.5 Companion Dx 182
8.3.6 Eiken Chemical 183
8.3.7 Epigenomics 187
8.3.8 Exact Sciences 191
8.3.9 ExiQon 196
8.3.10 Fujirebio (Miraca Holdings) 198
8.3.11 GeneNews 201
8.3.12 GenomicTree 202
8.3.13 Immunostics 204
8.3.14 Kyowa Medex 207
8.3.15 MDx Health (was OncoMethylome) 209
8.3.16 Merck Millipore 211
8.3.17 Metabiomics 214
8.3.18 Mode Diagnostics 216
8.3.19 Oncocyte (Bio Time) 218
8.3.20 Quest Diagnostics 220
8.3.21 R-Biopharm 223
8.3.22 Randox Laboratories 226
8.3.23 ScheBo Biotech 228
8.3.24 SciMarket Technologies 231
8.3.25 Siemens Healthcare 232
8.3.26 Signature Diagnostics 235
8.3.27 Sysmex 237
8.3.28 Veda Lab 239

9 Market Drivers, Opportunities and Barriers 241
9.1 Market Drivers 241
9.1.1 Uptake of Pipeline Biomarker Tests 241
9.1.2 Increasing Incidence of Colorectal Cancer and Improvements in Treatment 243
9.1.3 Patient Reluctance to Colonoscopies in Opportunistic CRC Screening 244
9.1.4 Increasing Volume of FOB Tests in Emerging Markets 245
9.1.5 Increased Pressure on Endoscopy Services 245
9.2 Opportunities 246
9.2.1 Blood Tests 246
9.2.2 Increasing CRC Screening Compliance 246
9.2.3 Integration of CRC Screening Tests with Prognostic Tests and Other Screening Programs 248
9.2.4 Emerging Markets 250
9.3 Market Barriers 251
9.3.1 Cultural and Social Resistance to Stool Tests 251
9.3.2 CRC Screening Awareness and Education 251
9.3.3 Reimbursement 252
9.3.4 Local Requirements 253
9.3.5 Test Complexity 256
9.3.6 Patenting Issues 257

10 Country Outlooks & Forecasts 258
10.1 APAC Markets Overview 258
10.2 Japan Market Analysis 262
10.3 China Market Analysis 264
10.4 India Market Analysis 265

11 Appendix 268
11.1 Abbreviations 268
11.2 Bibliography 270
11.3 Research Methodology 313
11.3.1 Coverage 313
11.3.2 Secondary Research 314
11.3.3 Forecasting Methodology 314
11.4 Physicians and Specialists Included in this Study 317
11.5 Primary Research 318
11.6 About the Authors 319
11.6.1 Analysts 319
11.6.2 Global Head of Healthcare 320
11.7 About GlobalData 321
11.8 Disclaimer 321

List of Table


Table 1: Initial Presenting Symptoms of Colorectal Cancer 29
Table 2: TNM Classification System to Stage CRC 37
Table 3: Stage Grouping for CRC 38
Table 4: Stage II CRC Sub-Divisions 38
Table 5: Stage III CRC Sub-Divisions 39
Table 6: Stage IV CRC Sub-Divisions 39
Table 7: Dukes System of CRC Classification 40
Table 8: Treatment Guidelines for Colorectal Cancer 41
Table 9: Surgical Options for Colorectal Cancer 41
Table 10: Treatment Alternatives for CRC 43
Table 11: Incident Cases of Colorectal Cancer, Ages

List of Chart


Figure 1: Colorectal Cancer Staging 25
Figure 2: APAC Trends in Colorectal Cancer Incidence, 2010-2019 45
Figure 3: Total Costs of Colorectal Cancer to Society in Japan, 2010-2019 48
Figure 4: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen 50
Figure 5: Fecal Occult Blood Test Lateral Flow Device Architecture 54
Figure 6: Biohit Colonview (example of immuno-FOB test) 55
Figure 7: Beckman Coulter Hemoccult-ICT (example of immuno-FOB test) 56
Figure 8: Veda Labs Easy Reader Immuno-FOB Test LFD Reader 62
Figure 9: OC-Hemodia Agglutination FOB Test (manually performed) 67
Figure 10: OC-Sensor/Diana FOB Test Sample Cartridge 68
Figure 11: OC-Sensor/Diana FOB Test Instrument 69
Figure 12: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction 70
Figure 13: Sentinel Diagnostic Sentifob Instrument 71
Figure 14: Alere CI5 NS-Plus Instrument 72
Figure 15: Orion Diagnostics Quikread FOB Test and Instrument 73
Figure 16: Basic PCR Process 80
Figure 17: MS9 PCR Response Curve 92
Figure 18: Proposed ColoGuard Patient Stool Sample Collection Kit 121
Figure 19: Exact Sciences Automated Sample Processing WorkStation 122
Figure 20: Colox Kit Contents 128
Figure 21: Measure Fecal Occult Blood Test 147
Figure 22: PanC-Dx Multiplex Detection of CRC-specific Biomarker 156
Figure 23: APAC Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 259
Figure 24: Forecast for Numbers of In-vitro CRC Screening Tests in APAC Region, 2010-2019 260
Figure 25: APACShare of Fecal Occult Blood Tests, by Brand, 2012 261
Figure 26: Japan Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 262
Figure 27: China Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 264
Figure 28: India Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 266

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *